A new survey conducted by the National MS Society (NMSS) reveals that 40% of respondents “altered or stopped taking their [MS-associated] medication” due to the medication(s) high costs.
NMSS also highlights that in 2019, the median price for disease modifying therapy for MS was $88,000, and that in 2020, these prices have already increased. The impact this type of pricing has on individuals living with MS is immense, and this new survey highlights one of the most heartbreaking results.
Please read more about the survey here.
